Your session is about to expire
← Back to Search
Cohort 1: Camoteskimab 7 mg/kg for Adult Onset Still's Disease
Study Summary
This trial is testing a new drug to see if it is safe and effective for people with AOSD.
- Adult Onset Still's Disease
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many individuals have signed up to partake in this experiment?
"This investigation necessitates the involvement of 12 compliant patients, who meet specific enrollment criteria. Two potential sites where study participation is accepted are Triwest Research Associates in El Cajon, California and University of Florida's Division of Rheumatology in Columbia, Maryland."
Am I eligible to join the experiment?
"This clinical trial is seeking twelve individuals suffering from adult-onset Still's disease within the ages of 18 and 75. Successful applicants must meet these conditions to be accepted into the study."
Does this trial include elderly individuals in its recruitment process?
"According to the guidelines, individuals aged 18 and above but below 75 can be included in this medical trial."
Is enrollment for this study currently open to participants?
"Affirmative. The clinicaltrials.gov portal states that this ongoing medical trial, initially posted on March 25th 2021, is actively seeking participants. There needs to be 12 individuals recruited from 10 different sites for the study's completion."
Has the FDA approved AEVI-007 (CERC-007, AVTX-007)?
"Our team at Power gave AEVI-007 (CERC-007, AVTX-007) a ranking of 1 on the safety scale because this is an early clinical trial; there exists only limited evidence to suggest that it is both safe and effective."
How many sites are administering this clinical research?
"Currently, this clinical trial is enrolling patients across 10 sites. These locations include El Cajon, Columbia and La Mesa in addition to 7 other cities. To reduce travel needs during the study period, it is suggested that you select the nearest clinic for your participation."
Share this study with friends
Copy Link
Messenger